Literature DB >> 10783073

Improved synthesis of paroxetine hydrochloride propan-2-ol solvate through one of metabolites in humans, and characterization of the solvate crystals.

K Sugi1, N Itaya, T Katsura, M Igi, S Yamazaki, T Ishibashi, T Yamaoka, Y Kawada, Y Tagami, M Otsuki, T Ohshima.   

Abstract

Paroxetine, a potent and selective inhibitor of 5-hydroxytryptamine (serotonin) uptake, was prepared through a piperidine derivative, which was reported to be one of the paroxetine metabolites in humans. Thus, the piperidine derivative was converted to its N-tert-butoxycarbonyl (N-Boc) derivative, which was then converted to N-Boc paroxetine. Paroxetine hydrochloride propan-2-ol (isopropyl alcohol (IPA)) solvate crystals were directly obtained from the N-Boc paroxetine by adding hydrogen chloride to the N-Boc paroxetine IPA solution. The amount of IPA content in the crystals was reduced by drying with a continuous change of powder X-ray diffraction patterns. Other characterizations of the solvate crystals were also conducted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10783073     DOI: 10.1248/cpb.48.529

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  3 in total

1.  Rapid Construction of (-)-Paroxetine and (-)-Femoxetine via N-Heterocyclic Carbene Catalyzed Homoenolate Addition to Nitroalkenes.

Authors:  Nicholas A White; Kerem E Ozboya; Darrin M Flanigan; Tomislav Rovis
Journal:  Asian J Org Chem       Date:  2014-04       Impact factor: 3.319

2.  Late-stage oxidative C(sp3)-H methylation.

Authors:  Kaibo Feng; Raundi E Quevedo; Jeffrey T Kohrt; Martins S Oderinde; Usa Reilly; M Christina White
Journal:  Nature       Date:  2020-03-16       Impact factor: 49.962

3.  Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation.

Authors:  Soraia Silva; Joana Bicker; Carla Fonseca; Nuno R Ferreira; Carla Vitorino; Gilberto Alves; Amílcar Falcão; Ana Fortuna
Journal:  Front Pharmacol       Date:  2021-12-02       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.